Lorenzo-Villalba Noel, Zulfiqar Abrar-Ahmad, Auburtin Marc, Schuhmacher Marie Helene, Meyer Alain, Maouche Yasmine, Keller Olivier, Andres Emmanuel
Service de Médecine Interne, Diabète et Maladies Métaboliques, Hôpitaux Universitaires de Strasboug, Strasbourg France.
Service de Médecine Interne, Centre Hospitalier d'Epinal, Epinal, France.
Eur J Case Rep Intern Med. 2020 May 7;7(6):001702. doi: 10.12890/2020_001702. eCollection 2020.
We report three cases of severe thrombocytopenia during COVID-19 infection associated with either cutaneous purpura or mucosal bleeding. The initial investigations ruled out other causes of thrombocytopenia. Two of the patients were treated with intravenous immunoglobulins and eltrombopag, while the third recovered spontaneously. A good clinical and biological response was achieved in all patients leading to hospital discharge.
Immune thrombocytopenia should be considered in COVID-19-infected patients presenting with thrombocytopenia.Coronavirus-related thrombocytopenia can be severe and life-threatening.Despite the severity of coronavirus-related immune thrombocytopenia, recovery may be spontaneous or achieved following immunoglobulin or platelet growth factor administration.
我们报告了3例新型冠状病毒肺炎（COVID-19）感染期间出现严重血小板减少症的病例，伴有皮肤紫癜或黏膜出血。初步检查排除了血小板减少症的其他病因。其中2例患者接受了静脉注射免疫球蛋白和艾曲泊帕治疗，而第3例患者自行康复。所有患者均取得了良好的临床和生物学反应，得以出院。
对于出现血小板减少症的COVID-19感染患者，应考虑免疫性血小板减少症。冠状病毒相关的血小板减少症可能很严重，甚至危及生命。尽管冠状病毒相关的免疫性血小板减少症很严重，但恢复情况可能是自发的，或在给予免疫球蛋白或血小板生长因子后实现。
